3aZEVvoRtp6McXy8TuIlR6lERn067Z

Investor Relations

NYSE: NVRO

Price

61.67 -1.98 ( -3.11% ) 2:08 8/15/18 Pricing delayed 20 minutes

Volume 358,260

Recent News

See All
August 2, 2018 Nevro Reports Second Quarter 2018 Financial Results
Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today reported financial results for the three and six months ended June 30, 2018. Second Quarter Financial Results Revenue for the three months ended June 30, 2018 was $96.1 million versus $78.0 million during the same period of the prior year, representing 23% growth as reported. U.S. revenue for the three months ended June 30, 2018 was $79.9 million, representing 27% growth as reported. International revenue was $16.2 million, representing growth of 4% in constant currency and 8% on an as-reported basis. The increase in revenue was primarily attributable to the continued adoption of the Senza system. Gross profit for the three months ended June 30, 2018 was $67.9 million, representing a 71% gross margin, up from $53.9 million, representing a 69% gross margin, in the same period of the prior year. Operating expenses for the three months...
July 30, 2018 Nevro Announces Patent Litigation Update
Parties File to Dismiss Remaining Claims - Boston Scientific Represents It Has No Plans to Launch High Frequency Products Nevro Corp. (NYSE: NVRO), a global medical technology company that is providing innovative evidence-based solutions for the treatment of chronic pain, announced that it has filed with Boston Scientific a joint statement proposing dismissal of the declaratory judgment claims that remain outstanding in their patent dispute on the basis of Boston Scientific's representations to the court that it has no plans to launch a high frequency product in the U.S. Nevro's complaint in this case, filed in November 2016, relied in part on Boston Scientific's announced plans to release early in 2017 the results of its ACCELERATE study of high-frequency SCS therapies.  The complaint anticipated that, based on those study results, Boston Scientific would imminently seek FDA approval and commercially launch a high-frequency product. Since Nevro's complaint was filed, Boston...
July 25, 2018 Nevro Announces Patent Litigation Update
Summary Judgment Ruling Affirms Method Claims Covering 1.5kHz to 100kHz Frequency Range Nevro Corp. (NYSE: NVRO), a global medical technology company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that the district court, in its patent dispute with Boston Scientific, issued an order on claim construction and summary judgment. In the order, the Court ruled in Nevro's favor with regard to six method claims in three Nevro patents, finding them patent eligible and rejecting Boston Scientific's arguments that the claims were invalid as indefinite.  Specifically, the claims upheld in this ruling are 11, 21 and 23 of U.S. Patent No. 8,359,102, claim 18 of U.S. Patent No. 8,792,988, and claims 1 and 5 of U.S. Patent No. 8,768,472.  Collectively, these six claims cover methods for delivering SCS therapy at frequencies between 1.5 kHz and 100 kHz. Prior to the filing of this lawsuit, Boston Scientific filed two petitions challenging the...

About Nevro

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the SENZA® spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. The SENZA® system is the only SCS system that delivers Nevro's proprietary HF10™ therapy. Senza, Senza II, HF10, Nevro and the Nevro logo are trademarks of Nevro.

Senza, HF10, Nevro, and the Nevro logo are trademarks of Nevro Corp.